Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Next Previous
Drug Profile

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Alternative Names: Aidixi; PF-08046051; RC 48; RC 48-ADC; Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate - Yantai Rongchang Pharmaceutical

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yantai Rongchang Biological Engineering
  • Developer Pfizer; RemeGen; Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Registered Urogenital cancer
  • Preregistration HER2 positive breast cancer
  • Phase III Adenocarcinoma
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gynaecological cancer; Malignant melanoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in China (IV, Injection)
  • 28 Jun 2026 Efficacy and adverse event data from phase II trial in Gastric cancer released by RemeGen
  • 29 May 2026 Efficacy and adverse evenet data from a phase II trial in Breast cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top